# Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

> **NCT05946122** · PHASE1 · UNKNOWN · sponsor: **Minia University** · enrollment: 106 (estimated)

## Conditions studied

- Renal Protection

## Interventions

- **DRUG:** Atorvastatin 40 Mg Oral Tablet
- **DRUG:** placebo drug

## Key facts

- **NCT ID:** NCT05946122
- **Lead sponsor:** Minia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-30
- **Primary completion:** 2023-12-12
- **Final completion:** 2023-12-30
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05946122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05946122, "Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05946122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*